BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/2/2021 12:29:13 PM | Browse: 28 | Download: 82
Publication Name World Journal of Clinical Cases
Manuscript ID 61429
Country/Territory China
Received
2020-12-07 01:49
Peer-Review Started
2020-12-07 01:50
To Make the First Decision
Return for Revision
2020-12-30 19:51
Revised
2021-01-10 17:29
Second Decision
2021-01-27 08:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-01-28 05:06
Articles in Press
2021-01-28 05:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
2021-02-07 08:27
Typeset the Manuscript
2021-03-15 02:16
Publish the Manuscript Online
2021-04-02 12:29
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma: A case report
Manuscript Source Unsolicited Manuscript
All Author List Xu-Yan Hu, Yu-Cheng Fei, Wen-Chao Zhou, Jin-Miao Zhu and Dong-Lai Lv
ORCID
Author(s) ORCID Number
Xu-Yan Hu http://orcid.org/0000-0002-7651-4492
Yu-Cheng Fei http://orcid.org/0000-0001-7137-5625
Wen-Chao Zhou http://orcid.org/0000-0001-5841-3842
Jin-Miao Zhu http://orcid.org/0000-0001-7281-989X
Dong-Lai Lv http://orcid.org/0000-0003-4128-6853
Funding Agency and Grant Number
Funding Agency Grant Number
Natural Science Foundation Project of Anhui Province 1808085MH267
Key Research and Development Project of Anhui Province 202004a07020020
Corresponding Author Dong-Lai Lv, BPhty, DVSc, MD, Chief Doctor, Doctor, Department of Clinical Oncology, 901 Hospital of Joint Logistic Support Force, No. 424 West Changjiang Road, Shushan District, Hefei 230031, Anhui, China. lvxunhuan@163.com
Key Words Osimertinib; Retreatment; Epidermal growth factor receptor; Tyrosine kinase inhibitor; Non-small cell lung cancer; Case report
Core Tip Osimertinib is the first-line recommended treatment for adult patients with epidermal growth factor receptor mutation positive advanced or metastatic non-small cell lung cancer. Once drug-resistance occurs in osimertinib, the standard of care is to discontinue the tyrosine kinase inhibitor. To the best of our knowledge, this is the first report of successful re-challenge and tri-challenge with osimertinib administered via multiple re-sensitization chemotherapy protocols. This case provides a useful reference for prolonging the efficacy of osimertinib.
Publish Date 2021-04-02 12:29
Citation Hu XY, Fei YC, Zhou WC, Zhu JM, Lv DL. Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(11): 2627-2633
URL https://www.wjgnet.com/2307-8960/full/v9/i11/2627.htm
DOI https://dx.doi.org/10.12998/wjcc.v9.i11.2627
Full Article (PDF) WJCC-9-2627.pdf
Full Article (Word) WJCC-9-2627.docx
Manuscript File 61429_Auto_Edited_LM-Webster J-Clear.docx
Answering Reviewers 61429-Answering reviewers.pdf
Audio Core Tip 61429-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 61429-Conflict-of-interest statement.pdf
Copyright License Agreement 61429-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 61429-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s) 61429-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate 61429-Language certificate.pdf
Peer-review Report 61429-Peer-review(s).pdf
Scientific Misconduct Check 61429-Scientific misconduct check.pdf
Scientific Editor Work List 61429-Scientific editor work list.pdf